The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | ERADIC trial: preliminary results of MRD-guided ibrutinib plus venetoclax vs FCR
In this interview, Anne-Sophie Michallet, MD, Léon Bérard Center, Lyon, France, reports the preliminary findings, regarding efficacy and safety, of the Phase II ERADIC trial (NCT04010968) in the FILO (French Innovative Leukemia Organization) group, which compares a measurable residual disease (MRD)-guided combination of ibrutinib and venetoclax to standard immunochemotherapy (FCR) in patients with chronic lymphocytic leukemia (CLL). This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
